Genmab A/S (CPH:GMAB)

Market Cap	113.75B
Revenue (ttm)	24.48B
Net Income (ttm)	10.08B
Shares Out	61.57M
EPS (ttm)	159.78
PE Ratio	11.56
Forward PE	16.54
Dividend	n/a
Ex-Dividend Date	n/a

Volume	131,354
Average Volume	155,769
Open	1,817.50
Previous Close	1,867.50
Day's Range	1,807.00 - 1,863.50
52-Week Range	1,157.00 - 2,153.00
Beta	0.79
RSI	42.64
Earnings Date	Nov 6, 2025

About Genmab

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell no...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 2,682
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: GMAB

Financial Performance

In 2024, Genmab's revenue was $2.99 billion, an increase of 22.32% compared to the previous year's $2.44 billion. Earnings were $1.09 billion, an increase of 68.72%.

Financial numbers in USD